Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials

Abstract

We present the guideline for use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine. Treatment using yttrium-90-labeled anti-P-cadherin antibody injection in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown here are considered internationally useful as well. Only the original Japanese version is the formal document.

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models

“…1 Gamma or positron emitter radionuclide such as technetium-99m ( 99m Tc), indium-111 ( 111 In), gallium-68 ( 68 Ga) and fluorine-18 ( 18 F) labeled biological molecules are used for imaging process, 2 - 5 while beta or alpha emitter radionuclide such as leutitium-177 ( 177 Lu), yttrium-90 ( 90 Y), rhenium-188 ( 188 Re), actinium-225 ( 225 Ac) are used for therapeutic procedures. 6 - 9 A variety of radiolabeled regulatory peptides are in clinical trials and few are in clinical practice for imaging and therapy of NETs. NET imaging and therapy bases on peptide-receptor affinity.…”